Viatris VTRS
Viatris FY 2021: revenue $17.9B, up 50%; diluted EPS −$1.05
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001792044-22-000010
- Document
- 10-K
Key figures from this report
These are the numbers Viatris reported for the year ended Dec 31, 2021, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$17.9B+50% from $11.9B in FY 202010-K income statement, on EDGAR
- Diluted EPS−$1.05Against −$1.11 in FY 202010-K income statement, on EDGAR
- Cash and cash equivalents$701.2M−17% from $844.4M in FY 2020Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations$3.0B+145% from $1.2B in FY 202010-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Roivant Sciences ROIV public float $9.8B, Sep 30, 2025
- United Therapeutics UTHR public float $11.2B, Jun 30, 2025
- Neurocrine Biosciences NBIX public float $9.5B, Jun 30, 2025
- Exelixis EXEL public float $9.4B, Jul 4, 2025
- BIO-TECHNE TECH public float $9.1B, Dec 31, 2025
